Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study
- PMID: 7735558
- DOI: 10.1097/00019606-199503000-00011
Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study
Abstract
All the factors that influence prognosis in patients with osteosarcomas have not been fully determined. One reported predictor of poor outcome is increased multi-drug resistant gene (mdr-1) expression, as measured by reverse transcription and polymerase chain reaction (RT-PCR). We examined whether immunostaining for p-glycoprotein, the protein product of mdr-1, could be used instead of RT-PCR to indicate the presence of the multidrug-resistant phenotype. The sensitivity of the immunostaining was determined using KB cell sublines. For 13 cases of osteosarcoma, samples were immunostained for p-glycoprotein and the levels of mdr-1 expression quantitated with use of RT-PCR. Three osteosarcomas with undetectable levels of mdr-1 expression by RT-PCR were negative immunohistochemically. Ten cases showed mdr-1 expression ranging from approximately 1 to 32 copies of mdr-1 mRNA/cell. Of these cases, five cases contained occasional tumour cells with positive immunostaining. There was no correlation between levels of expression and the presence or number of immunoreactive cells. These results indicate that the presence of p-glycoprotein immunostaining does not reliably correlate with the level of mdr-1 expression. However it may be useful in conjunction with RT-PCR to further define different subgroups of osteosarcomas that may have different prognoses, and this is currently under investigation.
Similar articles
-
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.Virchows Arch. 1997 Feb;430(2):99-105. doi: 10.1007/BF01008030. Virchows Arch. 1997. PMID: 9083512
-
Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.J Natl Cancer Inst. 1994 Oct 19;86(20):1539-45. doi: 10.1093/jnci/86.20.1539. J Natl Cancer Inst. 1994. PMID: 7932810
-
[P-glycoprotein expression in osteosarcoma].Pathologe. 1996 Jan;17(1):50-5. doi: 10.1007/s002920050134. Pathologe. 1996. PMID: 8685096 German.
-
Molecular diagnosis of multidrug resistance.Cancer Treat Res. 1994;73:129-47. doi: 10.1007/978-1-4615-2632-2_7. Cancer Treat Res. 1994. PMID: 7710903 Review. No abstract available.
-
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.Oncotarget. 2016 Dec 13;7(50):83502-83513. doi: 10.18632/oncotarget.13148. Oncotarget. 2016. PMID: 27835872 Free PMC article. Review.
Cited by
-
Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.Virchows Arch. 1997 Feb;430(2):99-105. doi: 10.1007/BF01008030. Virchows Arch. 1997. PMID: 9083512
-
P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.Br J Cancer. 1998 Sep;78(6):757-9. doi: 10.1038/bjc.1998.573. Br J Cancer. 1998. PMID: 9743295 Free PMC article.
-
Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.Sarcoma. 2008;2008:874075. doi: 10.1155/2008/874075. Epub 2009 Feb 25. Sarcoma. 2008. PMID: 19266050 Free PMC article.
-
Quantitative analysis of multidrug resistance gene expression in human osteosarcomas.Br J Cancer. 1996 Oct;74(7):1046-50. doi: 10.1038/bjc.1996.487. Br J Cancer. 1996. PMID: 8855972 Free PMC article.
-
Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.Clin Orthop Relat Res. 2013 Mar;471(3):915-25. doi: 10.1007/s11999-012-2610-2. Clin Orthop Relat Res. 2013. PMID: 23011844 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources